Cancer Stem Cells and Immunotherapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 634

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Medical Biotechnology, Poznan University of Medical Sciences, 61-866 Poznan, Poland
2. Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Center, 61-866 Poznan, Poland
Interests: melanoma; melanoma vaccines; cancer stem cells; melanoma stem cells; cancer immunotherapy; cancer immunology; acute-phase response; IL-6; soluble IL-6 receptor; immunotherapy clinical trials
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
College of Medicine, University of Cincinnati, Cincinnati, OH, USA
Interests: breast cancer; tissue specific cancer stem cells; immunotherapies; metastasis; breast cancer stem cells; autophagy; signal transduction pathways; DNA repair; cancer metabolism; tumor microenvironment; therapy resistance; combination therapies

Special Issue Information

Dear Colleagues,

Cancer stem cells (CSCs) are a small sub-population of cancer cells, with characteristics that are associated with normal stem cells such as self-renewal and differentiating cells. CSCs predominantly reside in various tissue-specific tumors as a distinct population of cells with high migration and invasive capacity, and promote relapse and metastasis by giving rise to new tumors at the secondary site. Chemotherapies and radiotherapies are effective in killing bulk cancer cells, but not fully effective in eradicating these CSCs due to their special features such as higher expression of efflux transporters, resistance to apoptosis and an enhanced mechanism of DNA repair. Therefore, the development of specific therapies aimed at CSCs is urgently needed for the enhancement of cancer patient survival, especially for patients with metastases. Cancer immunotherapy is an important therapeutic strategy and shown imperative outcomes in curing cancer. However, recent studies showed that CSCs depicts a low expression of immune cell markers such as MHC I molecules, NK cells receptors and innate immune receptors, which facilitates escape from immune cells, NK cells and T-cells. Therefore, further various immunological approaches and improvements in immunotherapies are necessary for targeting CSCs.

Prof. Dr. Andrzej Mackiewicz
Dr. Kanakaraju Manupati
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer stem cells
  • CSC-specific biomarkers
  • immunotherapies
  • signaling transduction pathways
  • tumor microenvironment
  • metastasis
  • therapy resistance
  • DNA repair
  • cellular metabolism
  • combination therapies

Published Papers

This special issue is now open for submission.
Back to TopTop